Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jhodi M WebsterUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0001-8230-6174
Ya-Ting YangUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0003-4671-8061
Aidan T MillerUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0002-4931-9747
Asta ZaneUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0002-9193-5797
Kasandra ScholzUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0001-8724-5454
William J StoneUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.
Nikhita MudiumUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.
Nicole J Corbin-SteinUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0003-0820-0085
Woong-Jai WonUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0009-0007-3396-6572
Anna C StollUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0001-7135-121X
Kelsey M GreathouseUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0002-4045-8708
Noelle H CooperUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.
Lillian F LongUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.
Phaedra N ManuelUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.
Jeremy H HerskowitzUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0002-7227-1470
Talene A YacoubianUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0003-2227-7310
Daniel J TyrrellUniversity of Alabama at Birmingham, Department of Pathology, Division of Molecular and Cellular Pathology, Birmingham, AL, 35294.ORCID 0000-0002-0811-6724
Ivette M SandovalBarrow Neurological Institute, Department of Translational Neuroscience; Phoenix, AZ, 85013.
Fredric P ManfredssonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815.ORCID 0000-0001-5802-5487
Jeffrey H KordowerAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815.ORCID 0000-0003-0407-1861
Ashley S HarmsUniversity of Alabama at Birmingham, Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, 35294.ORCID 0000-0002-7054-2812
Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Multi-parameter, analytic flow cytometerS10OD032296 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2022 to 2022
Alzheimer's (AD) and Parkinson disease (PD) pathology often co-occur. Amyloid-β and phosphorylated tau are found in 30-50% of idiopathic PD cases, while α-synuclein inclusions are present in 50% of AD cases. These co-pathologies are linked to increased mortality and earlier onset of cognitive decline. Immune activation is a hallmark of these neurodegenerative diseases, but current models primarily examine each pathology in isolation. How these co-pathologies drive inflammation and neuronal loss remains poorly understood. We therefore developed a mouse model combining tau, amyloid-β, and α-synuclein. We found that co-pathologies synergistically trigger an amplified neuroimmune response, with expanded populations of CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and neuropathology. · full record | OpenQuestion